<DOC>
	<DOCNO>NCT00814125</DOCNO>
	<brief_summary>To compare difference ARIMIDEX group tamoxifen group incidence abnormal endometrial histological finding arise treatment commence .</brief_summary>
	<brief_title>ATAC - Endometrial Sub-Protocol</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Patients eligible entry main ATAC trial ( 1033IL/0029 ) Not receive previous tamoxifen , whatever reason Not undergone hysterectomy hysterectomy plan within next 6 year No previous endometrial ablation Excluded entry main ATAC trial ( 1033IL/0029 ) . As detailed Section 4.4 main ATAC trial ( 1033IL/0029 )</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Endometrial</keyword>
	<keyword>Endometrial histological finding</keyword>
</DOC>